乙肝表面抗原对肝癌患者白细胞迁移无抑制作用。
Lack of leukocyte migration inhibition by hepatitis B surface antigen in hepatocellular carcinoma patients.
作者信息
Lee C S, Chang K J, Chen D S, Lin T Y
出版信息
Zhonghua Min Guo Wei Sheng Wu Xue Za Zhi. 1979 Sep;12(3):86-92.
Soluble part of hepatocellular carcinoma (HCC) tissue extracts with or without hepatitis B surface antigen (HBsAg) was tested against leukocytes of 13 histologically confirmed HCC patients. Inhibition of leukocyte migration was observed in 9 out of 13 cases when tested by soluble HCC extract containing HBsAg, while inhibition of lukocyte migration was observed in 8 out of 13 cases when tested by solublp greater than 0.05, by Fisher's exact test). In the meantime, soluble HCC extract with or without HBsAg did not significantly cause inhibition of leukocyte migration in 12 non-HCC patients. Therefore, it is concluded that inhibition of leukocyte migration in HCC patients is caused by the tumor-associated antigen, not caused by HBsAg.
用含有或不含乙型肝炎表面抗原（HBsAg）的肝细胞癌（HCC）组织提取物的可溶部分，对13例经组织学确诊的HCC患者的白细胞进行检测。当用含HBsAg的可溶性HCC提取物检测时，13例中有9例观察到白细胞迁移受到抑制，而当用可溶性HCC提取物检测时，13例中有8例观察到白细胞迁移受到抑制（通过Fisher精确检验，P大于0.05）。同时，含或不含HBsAg的可溶性HCC提取物在12例非HCC患者中未显著引起白细胞迁移抑制。因此，得出结论，HCC患者白细胞迁移的抑制是由肿瘤相关抗原引起的，而非由HBsAg引起。
Zotero 插件